Research advance on hemophagocytic lymphohistiocytosis.
- Author:
Yu NIU
1
;
Ai-Li HE
;
Wang-Gang ZHANG
Author Information
1. Department of Hematology, The Second Hospital, Xi'an Jiaotong University, Xi'an 710004, Shaanxi Province, China.
- Publication Type:Journal Article
- MeSH:
Humans;
Lymphohistiocytosis, Hemophagocytic;
diagnosis;
etiology;
immunology;
pathology;
therapy;
Mononuclear Phagocyte System
- From:
Journal of Experimental Hematology
2010;18(1):262-267
- CountryChina
- Language:Chinese
-
Abstract:
Hemophagocytic lymphohistiocytosis (HLH) is named as hemophagocytic syndrome (HPS) and is a complicated disease with reactive hyperplasia of mononuclear/macrophagocytic system. This disease characterised by release of massive cytokines and severe functional destruction of visceral organs, which results from immune function disturbance causing by various pathogenic factors. The cardinal clinical symptoms of HLH are prolonged fever, hepatosplenomegaly, cytopenia, elevated ferritin and triglycerides, low fibrinogen, symptom in nerve system and so on. Nevertheless, impaired function of natural killer cells and cytotoxic T-cell is characteristic for HLH. HLH has of two different types that may be difficult to distinguish from one another: a primary and a secondary form. The combined immunochemotherapy of dexamethasone, etoposide and cyclosporin A and hematopoietic stem cell transplantation are considered as the effective therapies for HLH. In this article, the recent advance in research on the etiological factors, pathogenesis, clinical manifestations, laboratory examination, diagnosis as well as recommended therapy of HLH were reviewed.
